...
首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Role of preoperative sublingual misoprostol in reducing need of analgesia and anaesthesia for gynaecological procedures in rural hospital
【24h】

Role of preoperative sublingual misoprostol in reducing need of analgesia and anaesthesia for gynaecological procedures in rural hospital

机译:术前舌下米索前列醇在减少农村医院妇科手术中镇痛和麻醉的需求中的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Many of gynaecological procedures require dilatation of cervix which may cause complications like excessive pain, cervical damage, creation of false tract and uterine perforation. Most of these may be done as outpatient procedures, which may reduce anaesthetic complications and decrease hospital stay. Misoprostol is a prostaglandin E1 which is proven to be effective in cervical priming hence reducing the fore mentioned complications. Methods: The study was randomized control trial followed a single bind style for two parallel groups. There were two groups, study group (n=100) and control group (n=100). The patients were recruited from the indoor as well as OPD requiring intrauterine procedure (viz D&C, hysteroscopy, HSG). The women of misoprostol group received, 200 microgram of misoprostol sublingualy and the women of placebo group received l mg folic acid 2 hours prior to the intrauterine procedure. Cervical dilatation, time required for the dilatation, cervical resistance, general experience of the patient, side effects, need of anaesthesia and complications were studied. Results: In present study mean post drug cervical dilatation was 4.08 ± 0.88 in study group which was more than control group 2.08 ± 0.27. It was statistically significant by using student't' test as p value Conclusions: Misoprostol PGE1 is commercially widely available, safe and cost effective drug which can be used as a cervical ripening/priming agent before all the gynaecological procedures in non-pregnant women as it increases the cervical dilatation and decreases the need of analgesia or anaesthesia.
机译:背景:许多妇科手术要求宫颈扩张,这可能会导致并发症,例如过度疼痛,宫颈损伤,假道和子宫穿孔。其中大多数可以通过门诊手术来完成,这可以减少麻醉并发症并减少住院时间。米索前列醇是一种前列腺素E1,已被证明可有效地促进宫颈启动,从而减少上述并发症。方法:该研究为随机对照试验,遵循两个平行组的单一结合方式。有两组,研究组(n = 100)和对照组(n = 100)。从室内以及需要宫内手术的OPD(即D&C,宫腔镜检查,HSG)中招募患者。米索前列醇组的妇女在子宫内手术前2小时接受舌下含200微克米索前列醇的治疗,而安慰剂组的妇女则接受1 mg叶酸。研究了宫颈扩张,扩张所需的时间,宫颈抵抗力,患者的一般经验,副作用,麻醉的需要和并发症。结果:在本研究中,研究组的平均药物后宫颈扩张为4.08±0.88,高于对照组的2.08±0.27。结论:米索前列醇PGE1是市售的,安全且具有成本效益的药物,在非孕妇的所有妇科手术前均可用作宫颈成熟剂/引发剂,因此具有统计学意义。它增加了子宫颈的扩张,并减少了镇痛或麻醉的需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号